No black box warning on record for Cerdelga

As of the latest FDA labeling reviewed, Cerdelga (ELIGLUSTAT) does not carry a black box warning. Standard warnings and precautions still apply — see the full Cerdelga medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS ECG Changes and Potential for Cardiac Arrhythmias : Not recommended in patients with pre-existing cardiac disease, long QT syndrome, and concomitant use of Class IA and Class III antiarrhythmics. ( 5.1 ) 5.1 ECG Changes and Potential for Cardiac Arrhythmias CERDELGA is predicted to cause increases in ECG intervals (PR, QTc, and QRS) at substantially elevated eliglustat p

No black box warning on record for Cerdelga

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS ECG Changes and Potential for Cardiac Arrhythmias : Not recommended in patients with pre-existing cardiac disease, long QT syndrome, and concomitant use of Class IA and Class III antiarrhythmics. ( 5.1 ) 5.1 ECG Changes and Potential for Cardiac Arrhythmias CERDELGA is predicted to cause increases in ECG intervals (PR, QTc, and QRS) at substantially elevated eliglustat p

Cerdelga Black Box Warning

No black box warning on record for Cerdelga

Other warnings & precautions

Cerdelga Black Box Warning

No black box warning on record for Cerdelga

Other warnings & precautions